Learn why early notified-body engagement is critical for combination products, including design rationale, risk controls, validation evidence and traceable documentation ahead of submission.

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, ...

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting ...

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new ...

At Booth 11F93 in Hall 11, the company will not only be showcasing its new look, it will also present solutions for sensitive ...

Lonza has nominated Pearl Huang as an independent member of its Board of Directors, bringing extensive pharmaceutical and ...

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's ...

The two-day programme addresses practical barriers to sustainable procurement, manufacturing and packaging — with ...

Partnership combines complementary expertise to help pharmaceutical formulators address complex solid oral dose development ...

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments ...

Helen explains how the NSF QP Alumni community helps Qualified Persons stay current through regulatory updates, peer discussions and shared experience, offering practical insight into evolving industr ...

Tablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the ...